Abivax SA (NASDAQ:ABVX) shared additional clinical data on Monday for obefazimod at the United European Gastroenterology (UEG) Meeting.

These data, from the Phase 3 ABTECT 8-Week Induction Trials investigating obefazimod for moderate-to-severely active ulcerative colitis, highlight additional efficacy endpoint data at week eight for patients with and without prior advanced therapy inadequate response (AT-IR).

A total of 1,272 patients were enrolled across the ABTECT trials.

In the pooled ABTECT 1 & 2 trials, treatment with once-daily obefazimod 50mg achieved clinically meaningful improvements in clinical response across all subgroups, including participants with prior AT-IR.

In participants without prior AT-IR, obefazimod 50mg delivered a placebo-adjusted difference ...